REVIEW ARTICLE



Histopathologic classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: achievements, limitations, and perspectives

Andrea Hinojosa-Azaola¹ · Ariadna Jiménez-González¹

Received: 12 April 2017 / Revised: 29 May 2017 / Accepted: 2 June 2017 / Published online: 14 June 2017 © International League of Associations for Rheumatology (ILAR) 2017

Abstract Clinical and histological factors have been identified as predictors of early and late renal outcome in ANCAassociated vasculitides (AAV). The presence and severity of kidney involvement at diagnosis are associated with poor prognosis in both patient and renal survival. Histologic findings remain the gold standard for diagnosing patients with AAV. In order to quantify the extent of the morphological parameters in the renal biopsies and to identify the histopathological lesions that predict renal outcome, several scoring systems have been proposed to systematically assess kidney biopsies in AAV. Renal pathologists from an international working group proposed in 2010 a new histopathological classification. This scheme comprises four general categories, based on the predominance of the glomerular histological lesions: focal (≥50% normal glomeruli); crescentic (≥50% glomeruli with cellular crescents); mixed (<50% normal, <50% crescentic, <50% globally sclerotic glomeruli), and sclerotic (≥50% globally sclerotic glomeruli). This article reviews the background and the main studies that have validated the histopathologic classification of ANCA-associated glomerulonephritis, the conclusions derived from these studies, and the perspectives for the assessment of renal outcome in AAV.

Keywords ANCA · Glomerulonephritis · Histological classification · Renal pathology · Vasculitis

Andrea Hinojosa-Azaola andreaha@yahoo.com

Introduction

The philosophy of classification addresses the questions: *How should we classify the world's entities? What is the relationship between classification and the world itself?* Classifications tell us whether two species belong to the same genus, or whether a genus is part of a particular family. They provide information for understanding the course of evolution and about evolution-ary relations among biological traits [1]. In Medicine, classification schemes have been developed in all fields and are used to understand the nature of the diseases, to categorize groups of patients for epidemiological, prognostic, or interventional studies, but more important, to assist in the clinical management of individual patients [2]. Histopathological classifications represent a good example of this.

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of diseases characterized by inflammation of small blood vessels, often leading to tissue destruction and organ failure. The main phenotypes of AAV are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Multisystem involvement is the hallmark of these diseases, being renal, in the form of glomerulonephritis, a common complication present in 38–70% of patients with GPA and 80–100% of MPA [3, 4].

Renal involvement is important in AAV because of its frequency and the impact on prognosis, especially in patient and kidney survival [5]. Clinically, it presents as rapidly progressive glomerulonephritis (RPGN), and histologically as a pauci-immune necrotizing crescentic glomerulonephritis. Positivity for ANCA may influence clinical and histological presentation in patients with pauci-immune glomerulonephritis [6, 7]. Also, variations in renal histology exist according to clinical and serologic subgroups. MPA patients present with glomerulonephritis characterized by more chronic injury

¹ Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Col. Sección XVI, Tlalpan, 14000 Mexico City, Mexico

compared to GPA patients, probably due to a delayed diagnosis, while MPO-ANCA positive patients present more abundant active and chronic histological lesions compared to PR3-ANCA positive patients [8].

A descriptive study of 74 American patients with ANCAnegative and ANCA-positive pauci-immune crescentic glomerulonephritis showed that ANCA-negative patients had lower estimated glomerular filtration rate (eGFR) and higher degree of interstitial fibrosis at presentation compared to ANCA-positive patients, with similar rates of end-stage renal disease (ESRD) at 1 year and comparable response to treatment in both groups [9].

Histopathological findings may vary among patients, and inter- and intraobserver variability may also exist [10]. Renal biopsy is useful to distinguish treatment-responsive active disease from treatment-unresponsive chronic states. For example, endocapillary lesions, glomerular tuft necrosis, and cellular and fibrocellular crescents represent acute and active lesions, whereas fibrous crescents, adhesion/synechia, and global or segmental glomerulosclerosis are chronic lesions [11]. Interstitial infiltrate consisting of mononuclear inflammatory cells and neutrophils, and less frequently, eosinophils are also characteristic [12]. Destruction of the basement membrane of Bowman's capsule, interstitial fibrosis and tubular atrophy, vasculitis, fibrinoid necrosis, and periglomerular granulomatous inflammation are other renal histological findings in AAV [11, 12].

In this article, we review the background and the main studies that have emerged since the development of the histopathologic classification of ANCA-associated glomerulonephritis in 2010, the conclusions derived from these studies and the perspectives for the assessment of renal outcome in AAV.

Predictors of renal outcome in AAV

Clinical and histological factors have been identified as predictors of early and late renal outcome in AAV. The presence and severity of kidney involvement at diagnosis are associated with poor prognosis in both patient and renal survival.

Clinical predictors of renal outcome include older age (>65 years), female gender, diagnosis of MPA and renal limited vasculitis, serum creatinine at diagnosis, proteinuria \geq 500 mg/day, arterial hypertension, treatment resistance, and relapses [5, 13, 14].

Among the histological factors, the percentage of normal glomeruli at diagnosis is the strongest predictor of GFR, showing a positive correlation [5]. Active lesions are associated with renal recovery and may be reversible, while chronic lesions, such as glomerulosclerosis, interstitial fibrosis, and tubular atrophy, are associated with poor renal prognosis [5, 15]. Moreover, recovery of renal function in patients initially dialysis dependent is associated with the amount of chronic lesions and arteriosclerosis, while long-term renal function correlates with chronic and acute tubulointerstitial lesions, tubular atrophy, and intraepithelial infiltrate [16–18].

Background

Histologic findings remain the gold standard for diagnosing patients with AAV. Renal biopsy in patients with GPA and evidence of active renal disease defined by urinary sediment demonstrates extracapillary proliferation in more than 91.5% of patients [12]. Repeat kidney biopsy is also helpful in differentiating patients with chronic damage from those with treatment-responsive active disease.

In the past, comparison between studies assessing renal outcome in patients with AAV was difficult due to differences in inclusion criteria, the type of histological lesions evaluated, and the definitions of renal outcome.

In order to quantify the extent of the morphological parameters in the renal biopsies and to identify the histopathological lesions that predicted renal outcome, several scoring systems were proposed to systematically assess kidney biopsies in AAV.

In 1996, Bajema et al. proposed the European Vasculitis Study Group (EUVAS) histological scoring system [10], based on a selected number of glomerular parameters (i.e., fibrinoid necrosis, extracapillary proliferation, sclerosis, periglomerular infiltrate, and granulomatous reaction) that were scored quantitatively as a percentage of the total number of glomeruli in the biopsy (quantitative data), while interstitial, tubular, and vascular parameters were scored either as dichotomous data or semi-quantitatively. The inter- and intra-observer agreement was good for quantitative glomerular parameters and less consistent for dichotomous data. When this system was validated in a multicenter European study comprising 157 patients with systemic vasculitis, the histologic parameters that correlated with renal outcome were the following: the percentage of normal glomeruli, glomerular sclerosis, diffuse interstitial infiltrates, tubular necrosis, and tubular atrophy [19]. Moreover, using this system in patients with repeated kidney biopsies, the mean percentage of normal glomeruli did not change over time, while the percentage of glomeruli with crescents decreased and glomerulosclerosis increased, independent of diagnosis, gender, age, time interval between biopsies, and treatment [20].

When the EUVAS histological scoring system was used to assess renal outcome in patients with ANCA-negative pauciimmune vasculitis, the histological findings and prognosis were comparable to those with ANCA-positive disease. Renal outcome was related to initial serum creatinine and to vasculitis-related organ involvement, but not to any histological parameter [7]. In 1998, Shigematsu et al. [21] proposed a histologic grading (acute activity index) and staging (chronicity index) for glomerular and interstitial lesions, in an effort to produce guidelines for the treatment of rapidly progressive nephritic syndrome. This system focused on the characterization of acute and chronic lesions among intracapillary, extracapillary, and interstitial lesions, using a sum score in each glomerular lesion and then calculating a mean score by dividing the sum score by the total number of glomeruli. This system was complicated, not suitable to select each glomerular and tubulointerstitial parameter for distribution as a prognostic marker, and did not consider the vascular lesions.

In 2003, Vergunst et al. [22] analyzed the predictive value of clinical, serological, and histological parameters for renal outcome in 160 patients with ANCA-associated glomerulonephritis and proposed an index for clinical use. The histological parameters included the following: normal glomeruli, fibrinoid necrosis, extracapillary proliferation, granulomas, interstitial edema, focal and diffuse infiltrates, fibrosis, tubular casts, tubular atrophy, tubular necrosis, sclerosis, mesangial proliferation, mesangial matrix expansion, arteriosclerosis, and infiltrates in arterioles. The proposed index is as follows:

 $\begin{aligned} \text{GFR at 1 } year &= 36.96 + 0.65^*(\text{GFR at time of renal biopsy}) \\ &+ 10.52 \; (if \; normal \; glomeruli \; present) \\ &+ 7.72 \; (if \; fibrinoid \; necrosis \; present) - 0.42^*(\text{age}). \end{aligned}$

This index shows that renal function (GFR) at the time of biopsy is the best predictor for renal function at 1 year, and that together with normal glomeruli, fibrinoid necrosis, and age, it explains more than 60% variation in GFR at 1 year.

In 2008, Joh et al. [11] proposed the Japanese scoring system for renal pathology in AAV, adding to the EUVAS score the assessment of the destruction of the tubular basement membrane, the basement membrane of Bowman's capsule, the presence of granulomatous lesions in the arteries as well as the interstitium, and vasculitis including endarteritis. This score evaluates quantitatively not only the glomerular lesions, but also tubulointerstitial and vascular lesions in percentages. Moreover, vascular lesions are scored based on the most severe lesions, and arcuate artery, interlobular artery, arteriole, venule, and peritubular capillary are evaluated with reference to sclerosis, necrosis, vasculitis, and thrombosis.

The histological classification of ANCA-associated glomerulonephritis

In order to assess the prognosis of patients with ANCAassociated glomerulonephritis at the time of renal biopsy and to facilitate uniform reporting worldwide, renal pathologists from an international working group proposed in 2010 a new histopathological classification. The aim was to design a classification scheme that would provide valuable information for clinicians and be easily adopted by pathologists in daily practice [23].

This classification derived from clinicopathological studies conducted within the EUVAS by an expert panel of renal pathologists known as the RENHIS (Renal Histology) group, consisting of experts from European centers in France, Italy, Germany, and the Netherlands [2]. Among the EUVAS studies that served as background for the classification were the CYCAZAREM (Cyclophosphamide versus Azathioprine as Remission Maintenance therapy for ANCA-associated vasculitis) and the MEPEX (Randomized trial of Plasma Exchange or High-dosage Methylprednisolone as adjunctive therapy for severe renal vasculitis) trials [24, 25].

The classification proposed by Berden et al. [26] is based on glomerular pathology as assessed by light microscopy and suggests a minimum of 10 whole glomeruli as adequate for evaluation. Hematoxylin and eosin, methenamine silver, and periodic acid-Schiff stainings are minimally required, while Masson trichrome staining or one of its variants can be helpful to visualize fibrinoid necrosis, acute tubular necrosis, and interstitial fibrosis.

The classification scheme comprises four general categories, based on the predominance of the glomerular histological lesions [26]:

- Focal: \geq 50% normal glomeruli.
- Crescentic: ≥50% glomeruli with cellular crescents.
- Mixed: <50% normal, <50% crescentic, <50% globally sclerotic glomeruli.
- Sclerotic: ≥50% globally sclerotic glomeruli.

The classification does not take into account comorbid diseases or overlap syndromes and provides definitions for the main histological lesions (normal glomeruli, cellular or fibrous crescents, global glomerulosclerosis). Because the classification is based on glomerular lesions only, it suggests that tubulointerstitial and vascular lesions are scored according to the previous EUVAS scheme [10].

Validation studies

Geographical differences in the incidence and expression of AAV have been demonstrated in Japan, Europe, and North America [27]. African Americans with pauci-immune glomerulonephritis are younger and more often MPO-ANCA positive compared to Caucasians [28]. Differences in clinical phenotypes also exist, with lower frequency of renal involvement in Japanese patients with GPA (12–63%) compared to over 70% in patients with GPA from Germany and USA [27]. The severity of kidney damage and differences in therapy

Table 1 Validation studies	from 2010 to 2013					
Study Study design	Berden et al. [26] EUVAS clinical trials	Berden et al. [49] EUVAS clinical trials	Chang et al. [29] Retrospective	Ellis et al. [30] Retrospective cohort	Iwakiri et al. [31] Retrospective	Togashi et al. [36] Retrospective
Number of patients	100	30	121	76	102	54
Age—years	$62.6(20.4 - 80.7)^{a}$	63.3 (16.8) ^b	57.2 (14.7) ^b	58 ^b	66.3 (11.3) ^b	66.9 (36–85) ^b
Gender— n (%)						
Male	54 (54)	16 (53)	64 (53)	43 (57)	54 (53)	28 (52)
Female	46 (46)	14 (47)	57 (47)	33 (43)	48 (47)	26 (48)
Geographical area	Europe (multicenter)	Europe Australia	China (sinole-center)	U.S. (single-center)	Japan (multicenter)	Japan (sinøle-center)
Diagnosis— n (%)						
GPA	39 (39)	15 (50)	49 (41)	43 (57)	3 (3)	0
MPA	61 (61)	15 (50)	68 (56)	31 (41)	97 (95)	25 (46)
EGPA	0	0	0	0	2 (2)	1 (2)
RLV	0	0	4 (3)	2 (3)	0	28 (52)
ANCA—n (%)						
pANCA/MPO	47 (47)	13 (43)	108 (89)	32 (42)	86 (84)	54 (100)
cANCA/PR3	45 (45)	17 (57)	13 (11)	30 (39)	5 (5)	0
Negative	2 (2)	0	0	14 (18)	11 (11)	0
Missing	3 (3)	0	0	0	0	0
Histological class— n (%)		26/30				
Focal	16 (16)	10 (38)	33 (27)	20 (26)	46 (45)	17 (31)
Crescentic	55 (55)	10 (38)	53 (44)	18 (24)	32 (31)	8 (15)
Mixed	16 (16)	6 (23)	24 (20)	27 (36)	18 (18)	19 (35)
Sclerotic	13 (13)	0	11 (9)	11 (14)	6 (6)	10 (19)
Conclusion	Phenotypical order of the classes corresponded to the order of severity of renal function impairment during follow-up.	Significant association between renal biopsy class and baseline eGFR. Association between tubulointerstitial lesions and renal function.	Histological classification reflected the severity of the initial renal impairment and predicted renal response to treatment and development of ESRD.	Association between histologic class and renal function at baseline and 1 year. Dialysis-dependent patients with sclerotic class on presentation had no response to therapy.	Histopathological classification was associated with eGFR at one year. Immunohistochemical staining for α-SMA expression might be useful to estimate renal outcome.	Phenotypical order of classes corresponded to severity of renal function impairment. No difference in patient survival among the four groups.
<i>GPA</i> granulomatosis with pol <i>pANCA/MPO</i> perinuclear AN actin, <i>eGFR</i> estimated glomet	yangiitis, <i>MPA</i> microscopi ICA/myeloperoxidase, <i>cA</i> A ular filtration rate	c polyangiitis, <i>EGPA</i> eosinc VCA/PR3 cytoplasmic ANC	philic granulomatosis with po A/proteinase 3, <i>EUVAS</i> Euroj	olyangiitis, RLV renal-limited v pean Vasculitis Study Group, E	asculitis, ANCA anti-neutroph SRD end-stage renal disease,	il cytoplasmic antibodies, α -SMA α -smooth muscle

^a Median (range) ^b Mean (SD or range)

Study design	Uniu et al. [3/] Retrospective	Hilhorst et al. [38] Retrospective cohort	Muso et al. [39] Retrospective	Hilhorst et al. [40] Retrospective cohort	Tanna et al. [41] Retrospective	Quintana et al. [42] Retrospective	Nohr et al. [33] Retrospective cohort
Number of patients	141	164	87	181	104	136	67
Age—years	49 (16.4) ^b	61 (14.6) ^b	$63 (17 - 85)^a$	$61.4(14.4)^{b}$	62.2 (17–3-87.2) ^a	62.1 ^b	$60 (14-89)^{b}$
Gender—n (%)							
Male	80 (57)	113 (69)	37 (43)	129 (71)	58 (56)	71 (52)	41 (61)
Female	61 (43)	51 (31)	50 (57)	52 (29)	46 (44)	65 (48)	26 (39)
Geographical area	Turkey (multicenter)	Netherlands	Japan (multicenter)	Netherlands	London	UK, Spain	Canadian
		(single-center)		(single-center)	(single-center)		
Diagnosis—n (%)		NA		NA	NA		NA
GPA	55 (39)		0			44 (32)	
MPA	20 (14)		87 (100)			80 (59)	
EGPA	0		0			0	
RLV	39 (28)		0	ı	ı	8 (6)	
Unknown	27 (19)		0	ı	ı	4(3)	
ANCA—n (%)							
pANCA/MPO	61 (43)	81(49)	76 (87)	92 (51)	49 (47)	76 (56)	39 (58)
cANCA/PR3	60 (43)	83 (51)	0	89 (49)	49 (47)	51 (37)	21 (31)
Double-positive	5 (4)	0	0	0	0	0	0
Negative	25 (18)	0	0	0	6 (6)	6 (7)	7 (11)
Missing	0		11 (13)	0	0	0	0
Histological class-n	(0_{0}^{\prime})						
Focal	31 (22)	81 (49)	40 (46)	51 (28)	23 (22)	35 (26)	15 (22)
Crescentic	69 (49)	43 (26)	7 (8)	77 (43)	26 (25)	31 (23)	25 (37)
Mixed	29 (21)	39 (24)	26 (30)	52 (29)	48 (46)	53 (39)	20 (30)
Sclerotic	12 (8)	1 (1)	14 (16)	1 (0.1)	7 (7)	17 (12)	7 (11)
Conclusion	Percentage of full	Patients classified as	Mixed class showed	The focal group had the	It may be of value	Confirmed predictive	The classification
	moon glomeruli	crescentic or mixed had	heterogeneity of	best renal survival	to combine the	value of histological	validated the
	should be noted	worse survival when the	histological activity	and the crescentic	histological	classification. Worse	association between
	in the pathology	percentage of normal	and chronicity,	group had the worst.	classification	renal outcome in	cellular crescents
	report; cases with	glomeruli was <25%.	which shows the	Histological groups	with tubular	patients with	and improvement in
	>50% at increased	Adding the percentage	insufficiency of the	were significantly	atrophy and	MPO-ANCA,	eGFR, and between
	risk of dialysis	of normal glomeruli	classification for	related to renal but no	percentage of	tubulointerstitial	globally sclerotic
	requirements.	improves the predictive	predicting progression	to patient survival.	normal glomeruli.	fibrosis and atrophy.	glomeruli and reduced
		value of the classification.	to ESRD.				eGFR.

^a Median (range)

^b Mean (SD or range)

Study Naidu et al. [43] Ford et Study design Naidu et al. [43] Ford et Retrospective Ford et Retrospective Number of patients 86 120 8 120 Number of patients 86 120 8 8 120 Number of patients 86 42.5 (15.2) ^b 66 (8-6 8 8 Male 42.5 (15.2) ^b 65 (8-6 8 8 120 Male 42.5 (15.2) ^b 66 (8-6 8 8 10 Temale India 42.49) 72 (60) 72 (60) 72 (60) Retrospective 86 11.01 72 (61) 73 (61) 8 8 Diagnosis—n $\%$ 34 (40) -	Ford et al. [46] Retrospective 120 66 (8–87) ^a 66 (8–87) ^a 66 (8–87) ^a 48 (40) Australia (single-center) NA NA - - - - - - - - - - - - - - - - -	Andreiana et al. [34] Retrospective 75 60 (53–68) ^a 60 (53–68) ^a 36 (48) 39 (52) Romania (single-center) NA	Córdova et al. [47] Retrospective 62 52 (34–61) 33 (61) México (single-center) 34 (55) 34 (55) 0 0 0 0 1(34)	Diaz-Crespo et al. [44] Retrospective 151 60 (22–85) ^b 66 (44) Spain (multicenter) 10 (6) 60 (40) 0 81 (54) 0	Kristensen et al. [45] Retrospective 87 62.9 (22–86) ^b 54 (62) 33 (38) Denmark (single-center) NA -
Number of patients 86 120 Age—years 42.5 (15.2) ^b 66 (8~8 Gender— n (%) 42 (49) 72 (60) Male 42 (49) 72 (60) Female 11dia 48 (40) Geographical area India 72 (60) Diagnosis— n (%) 34 (40) 48 (40) Diagnosis— n (%) 34 (40) - MPA 36 (42) - Diagnosis— n (%) 34 (40) - MPA 36 (42) - MPA 36 (42) - MPA 36 (42) - MPA 1 (1) - MINown 15 (17) - Avypical - 17 (14) Negative 33 (33) 0 Missing 0 0 Missing 0 0 0 Mised 13 (16) 33 (27) Mixed 16 (19) 33 (27) Mised 16 (19) 33 (27)	120 66 (8–87) ^a 72 (60) 48 (40) Australia (single-center) NA - - - - - - - - - - - - - - - - - -	75 60 (53–68) ^a 36 (48) 39 (52) Romania (single-center) NA 	62 52 (34–61) 24 (39) 38 (61) México (single-center) 34 (55) 34 (55) 20 (32) 0 8 (13) 0 21 (34)	151 60 (22–85) ^b 85 (56) 66 (44) Spain (multicenter) (multicenter) 10 (6) 60 (40) 0 81 (54) 0	87 62.9 (22–86) ^b 54 (62) 33 (38) Denmark (single-center) NA - -
Number of patients 86 120 Age—years $42.5 (15.2)^b$ $66 (8-5)^c$ Male $42.5 (15.2)^c$ $66 (8-5)^c$ Diagnosis— $n (\%)$ $72 (60)^c$ $72 (60)^c$ Diagnosis— $n (\%)$ $34 (40)^c$ -100^c Diagnosis— $n (\%)$ $34 (40)^c$ -100^c Diagnosis— $n (\%)$ $34 (40)^c$ -100^c MPA $36 (42)^c$ -100^c MROA— $n (\%)$ $53 (62)^c$ -100^c PANCA/MPO NA -100^c Avypical -100^c -100^c Negative $33 (36)^c$ 00^c	120 66 (8–87) ^a 72 (60) 48 (40) Australia (single-center) NA - - - - - - - - - - - - - - - - - -	75 60 (53–68) ^a 36 (48) 39 (52) Romania (single-center) NA 	62 52 (34–61) 24 (39) 38 (61) México (single-center) 34 (55) 20 (32) 0 8 (13) 0 21 (34)	151 60 (22–85) ^b 85 (56) 66 (44) Spain (multicenter) (multicenter) 10 (6) 60 (40) 0 81 (54) 0	87 62.9 (22–86) ^b 54 (62) 33 (38) Denmark (single-center) NA - -
Age—years $42.5 (15.2)^b$ $66 (8-8)^c$ Gender— $n (\%)$ Male $42 (49)$ $72 (60)$ Female $44 (51)$ $48 (40)$ Geographical area India $44 (51)$ $48 (40)$ Geographical area India $44 (51)$ $48 (40)$ Diagnosis— $n (\%)$ $33 (42)$ $66 (8-8)^{-3}$ Diagnosis— $n (\%)$ $34 (40)$ $-$ MPA $36 (42)$ $-$ EGPA $1 (1)$ $-$ MRV $ -$ RLV 0 $ -$ NA $35 (42)$ $ -$ RLV 0 $ -$ NLOA— $n (\%)$ $53 (62)$ $ -$ Anypical $ -$ <t< td=""><td>66 (8–87)^a 72 (60) 48 (40) Australia (single-center) NA - - - - - - - - - - - - - - - - - -</td><td>60 (53–68)^a 36 (48) 39 (52) Romania (single-center) NA </td><td>52 (34–61) 24 (39) 38 (61) México (single-center) 34 (55) 20 (32) 0 8 (13) 0 21 (34)</td><td>60 (22–85)^b 85 (56) 66 (44) Spain (multicenter) (multicenter) 10 (6) 60 (40) 0 81 (54) 0</td><td>62.9 (22–86)^b 54 (62) 33 (38) Denmark (single-center) NA - -</td></t<>	66 (8–87) ^a 72 (60) 48 (40) Australia (single-center) NA - - - - - - - - - - - - - - - - - -	60 (53–68) ^a 36 (48) 39 (52) Romania (single-center) NA 	52 (34–61) 24 (39) 38 (61) México (single-center) 34 (55) 20 (32) 0 8 (13) 0 21 (34)	60 (22–85) ^b 85 (56) 66 (44) Spain (multicenter) (multicenter) 10 (6) 60 (40) 0 81 (54) 0	62.9 (22–86) ^b 54 (62) 33 (38) Denmark (single-center) NA - -
Gender— n (%) 42 (49) 72 (60) Male 44 (51) 48 (40) Female 44 (51) 48 (40) Geographical area India Austral Diagnosis— n (%) $34 (40)$ Austral Diagnosis— n (%) $34 (40)$ NA GPA $34 (40)$ - Diagnosis— n (%) $34 (40)$ - MPA $36 (42)$ - MPA $36 (42)$ - MPA $36 (42)$ - MPA $1 (1)$ NA MPA $1 (1)$ - MPA $1 (1)$ - MPA $1 (1)$ - MILV 0 NA ANCA-m (%) $53 (62)$ - ANCA-MPO NA $28 (23)$ ANCA-MPO NA $28 (23)$ Alypical - 17 (14) Negative $33 (38)$ 0 Missing 0 0 Missing 0 0 Model $13 (16)$ $33 (23)$	72 (60) 48 (40) Australia (single-center) NA - - - - - - - - - - - - - - - - - -	36 (48) 39 (52) Romania (single-center) NA 	24 (39) 38 (61) México (single-center) 34 (55) 20 (32) 0 8 (13) 0 21 (34)	85 (56) 66 (44) Spain (multicenter) (multicenter) 60 (40) 0 81 (54) 0	54 (62) 33 (38) Denmark (single-center) NA - -
Male 42 (49) 72 (60) Female 44 (51) 48 (40) Geographical area India Austral Diagnosis— n (%) (single-center) (single-center) Diagnosis— n (%) 34 (40) NA GPA $34 (40)$ NA GPA $34 (40)$ - MPA $1(1)$ NA MPA $1(1)$ - MPA $1(1)$ - MPA $1(1)$ - MPA $1(1)$ - MRV 0 - MRV 0 - MPA $1(1)$ - ANCA— n (%) $53 (62)$ - ANCA/MPO NA $75 (63)$ ANCA/MPO NA $28 (23)$ Atypical - 17 (14) Negative $33 (38)$ 0 Missing 0 0 Missing 0 0 Missing 0 0 <td>72 (60) 48 (40) Australia (single-center) NA - - - - - - - - - - - - - - - - - -</td> <td>36 (48) 39 (52) Romania (single-center) NA </td> <td>24 (39) 38 (61) México (single-center) 34 (55) 20 (32) 0 8 (13) 0 21 (34)</td> <td>85 (56) 66 (44) Spain (multicenter) (multicenter) 60 (40) 0 81 (54) 0</td> <td>54 (62) 33 (38) Denmark (single-center) NA - -</td>	72 (60) 48 (40) Australia (single-center) NA - - - - - - - - - - - - - - - - - -	36 (48) 39 (52) Romania (single-center) NA 	24 (39) 38 (61) México (single-center) 34 (55) 20 (32) 0 8 (13) 0 21 (34)	85 (56) 66 (44) Spain (multicenter) (multicenter) 60 (40) 0 81 (54) 0	54 (62) 33 (38) Denmark (single-center) NA - -
Female 44 (51) 48 (40) Geographical area India Austral Diagnosis— n (%) (single-center) (single- bingle-center) (single- (single- center) Diagnosis— n (%) 34 (40) - (single- (single- center) NA Diagnosis— n (%) 34 (40) - - (single- (single- center) - Diagnosis— n (%) 34 (40) - - - - MPA 36 (42) 34 (40) - - - MPA 36 (42) 34 (40) - - - NLV 36 (42) 34 (40) - - - RLV 0 NA 35 (52) - - ANCA-MPO NA 15 (17) -	48 (40) Australia (single-center) NA - - - 75 (63) 28 (23) 17 (14)	39 (52) Romania (single-center) NA - -	38 (61) México (single-center) 34 (55) 20 (32) 0 8 (13) 0 21 (34)	66 (44) Spain (multicenter) 10 (6) 60 (40) 0 81 (54) 0	33 (38) Denmark (single-center) NA - - -
Geographical area India Austral Diagnosis— n (%) (single-center) (single-center) Diagnosis— n (%) 34 (40) NA GPA 34 (40) - MPA 36 (42) - MPA 36 (42) - MPA 36 (42) - MPA 1 (1) - MPA 1 (1) - RLV 0 - NCA— n (%) 53 (62) - ANCA-MPO NA 28 (23) ANCA/MPO NA 28 (23) Atypical - - Atypical - 17 (14) Negative 33 (38) 0 Missing 0 0 Missing 13 (16) 33 (23) Crescentic 15 (19) 33 (27) Mixed 16 (19) 33 (27)	Australia (single-center) NA - - - 75 (63) 28 (23) 17 (14)	Romania (single-center) NA - -	México (single-center) 34 (55) 20 (32) 0 8 (13) 0 21 (34)	Spain (multicenter) 10 (6) 60 (40) 0 81 (54) 0	Denmark (single-center) NA - - -
Diagnosis— $n(\%)$ (single-center) (single-center) Diagnosis— $n(\%)$ $34(40)$ NA GPA $34(40)$ $-$ MPA $36(42)$ $-$ MPA $36(42)$ $-$ MPA $1(1)$ $-$ MPA $1(1)$ $-$ MPA $1(1)$ $-$ NLV 0 $-$ NLOA— $n(\%)$ $53(62)$ $-$ ANCA- $n(\%)$ $53(62)$ $-$ ANCA- $n(\%)$ $53(62)$ $-$ ANCA- $n(\%)$ NA $28(23)$ Anypical $ -$ Atypical $ -$ Negative $33(38)$ 0 Missing 0 0 Missing 0 0 Missing $13(16)$ $34(28)$ Focal $13(16)$ $33(27)$ Mixed $16(19)$ $33(27)$	(single-center) NA - - - - - - - - - - - - - - - - - -	(single-center) NA - -	(single-center) 34 (55) 20 (32) 0 8 (13) 0 21 (34)	(multicenter) 10 (6) 60 (40) 0 81 (54) 0	(single-center) NA - - -
Diagnosis n (%)NAGPA 34 (40) $-$ MPA 36 (42) $-$ EGPA 1 (1) $-$ EGPA 1 (1) $-$ RLV 0 $-$ Nknown 15 (17) $-$ NCA $-m$ (%) 53 (62) $-$ ANCA $-m$ (%) 53 (62) $-$ ANCA $-m$ (%) 33 (38) 0 Mappical $ -$ Atypical $ -$ Negative 33 (38) 0 Missing 0 0 Missing 0 $-$ Missing 13 (16) 34 (28)Crescentic 13 (16) 33 (27)Mixed 16 (19) 33 (27)Schencic 12 (14) $-$	NA - - - - - - - - - - - - - - - - - - -	Υ	34 (55) 20 (32) 8 (13) 0 21 (34)	10 (6) 60 (40) 0 81 (54) 0	¥ 7
GPA $34 (40)$ $-$ MPA $36 (42)$ $-$ EGPA $1 (1)$ $-$ RLV 0 $-$ NLV 0 $-$ Unknown $15 (17)$ $-$ ANCA- $-n (\%)$ $53 (62)$ $-$ ANCA- $n (\%)$ $53 (62)$ $-$ ANCA- NPO NA $28 (23)$ Arypical $ 17 (14)$ Negative $33 (38)$ 0 Missing 0 0 Missing 0 0 Hitological class- $-n (\%)$ $84/86$ Focal $13 (16)$ $33 (27)$ Mixed $16 (19)$ $33 (27)$ Schemic $12 (14)$ $20 (17)$	- - - - - - - - - - - - - - - - - - -		34 (55) 20 (32) 8 (13) 0 21 (34)	10 (6) 60 (40) 0 81 (54) 0	1 1 1 1 1 1
MPA $36 (42)$ $-$ EGPA1 (1) $-$ RLV0 $-$ NLV0 $-$ Unknown $15 (17)$ $-$ ANCA $-m (\%)$ $53 (62)$ $-$ ANCA $-m (\%)$ $53 (62)$ $-$ ANCA $-m (\%)$ $33 (52)$ $75 (63)$ ANCA $-PR3$ NA $28 (23)$ Atypical $ 17 (14)$ Negative $33 (38)$ 0 Missing 0 0 Missing 0 0 Histological class- $n (\%)$ $84/86$ Focal $13 (16)$ $34 (28)$ Crescentic $13 (16)$ $33 (27)$ Mixed $16 (19)$ $33 (27)$ Schemic $12 (14)$ $20 (17)$	- - 75 (63) 28 (23) 17 (14)		20 (32) 0 8 (13) 0 21 (34)	60 (40) 0 81 (54) 0	
EGPA1 (1)-RLV015 (17)-Unknown15 (17)-ANCA $-m$ (%)53 (62)-ANCA/PR3NA75 (63)pANCA/PR3NA28 (23)Atypical-17 (14)Negative33 (38)0Missing00Missing00Focal13 (16)34 (28)Focal16 (19)33 (27)Mixed16 (19)33 (27)	- - 75 (63) 28 (23) 17 (14)		0 8 (13) 0 21 (34)	0 81 (54) 0	
RLV 0 - - Unknown 15 (17) - - ANCA \neg n (%) 53 (62) 53 (63) - ANCA \neg m (%) 53 (62) 75 (63) pANCA/PR3 NA 75 (63) cANCA/PR3 NA 28 (23) Atypical - 17 (14) Negative 33 (38) 0 Missing 0 0 Missing 0 0 Histological class—n (%) 84/86 34 (28) Focal 13 (16) 34 (28) Mixed 16 (19) 33 (27) Mixed 16 (19) 33 (27)	- 75 (63) 28 (23) 17 (14)	1	8 (13) 0 21 (34)	81 (54) 0	
Unknown 15 (17) - ANCA $-n$ (%) 53 (62) 53 (63) pANCA/MPO NA 75 (63) cANCA/PR3 NA 28 (23) Atypical - 17 (14) Atypical - 17 (14) Negative 33 (38) 0 Missing 0 0 Missing 0 0 Focal 13 (16) 34 (28) Crescentic 15 (19) 33 (27) Mixed 16 (19) 33 (27)	- 75 (63) 28 (23) 17 (14)		0 21 (34)	0	1
ANCA $-n$ (%) 53 (62) pANCA/MPO NA 75 (63) cANCA/PR3 NA 28 (23) cANCa/PR3 NA 28 (23) Atypical - 17 (14) Negative 33 (38) 0 Missing 0 0 Missing 0 0 Focal 13 (16) 34 (28) Crescentic 43 (51) 33 (27) Mixed 16 (19) 33 (27)	75 (63) 28 (23) 17 (14)		21 (34)		
$ \begin{array}{c ccccc} pANCA/MPO & NA & 75 (63) \\ cANCA/PR3 & NA & 28 (23) \\ Atypical & - & 17 (14) \\ Negative & 33 (38) & 0 \\ Nissing & 0 & 0 \\ Missing & 0 & 0 \\ Histological class-n (\%) & 84/86 & 34 (28) \\ Focal & 13 (16) & 34 (28) \\ Focal & 16 (19) & 33 (27) \\ Mixed & 16 (19) & 33 (27) \\ Schencic & 12 (10) & 20 (17) \\ Schencic & 12 (10) & 20 (17) \\ Schencic & 12 (10) & 20 (17) \\ \end{array} $	75 (63) 28 (23) 17 (14)		21 (34)		
cANCA/PR3 NA 28 (23) Atypical - 17 (14) Negative 33 (38) 0 Nissing 0 0 Missing 0 0 Histological class— n (%) 84/86 34 (28) Focal 13 (16) 34 (28) Mixed 16 (19) 33 (27) Mixed 16 (19) 33 (27)	28 (23) 17 (14)	57 (76)		96 (64)	49 (56)
Atypical-17 (14)Negative $33 (38)$ 0Negative $33 (38)$ 0Missing00Missing00Histological class— n (%) $84/86$ $34 (28)$ Focal13 (16) $34 (28)$ Crescentic43 (51) $33 (27)$ Mixed16 (19) $33 (27)$ Sclamic12 (10) $30 (21)$	17 (14)	18 (24)	35 (56)	21 (14)	38 (44)
Negative 33 (38) 0 Missing 0 0 0 Missing 0 $84/86$ 34 (28) Focal 13 (16) 34 (28) Crescentic 43 (51) 33 (27) Mixed 16 (19) 33 (27) Sclamic 12 (14) 32 (27)		0	0	0	0
Missing 0 0 0 Histological class— n (%) $84/86$ $34/28$ Focal 13 (16) $34 (28)$ Crescentic $43 (51)$ $33 (27)$ Mixed 16 (19) $33 (27)$ Schendic $12 (13)$ $33 (27)$	0	0	6 (10)	34 (22)	0
Histological class— n (%) $84/86$ Focal13 (16) $34 (28)$ Crescentic $43 (51)$ $33 (27)$ Mixed16 (19) $33 (27)$ Schemic $12 (1A)$ $20 (12)$	0	0	0	0	0
Focal 13 (16) 34 (28) Crescentic 43 (51) 33 (27) Mixed 16 (19) 33 (27) Schenzic 12 (14) 20 (17)			55/62		Unknown 9 (10)
Crescentic 43 (51) 33 (27) Mixed 16 (19) 33 (27) Schenotic 12 (14) 20 (12)	34 (28)	4 (5)	5 (9)	32 (21)	21 (24)
Mixed 16 (19) 33 (27) Scienceia 12 (14) 20 (17)	33 (27)	39 (52)	1 (2)	62 (41)	24 (28)
Selaratio 12 (14) 20 (17)	33 (27)	24 (32)	25 (45)	36 (24)	30 (34)
	20 (17)	8 (11)	24 (44)	21 (14)	3 (4)
Conclusion Histopathological class Reprod	Reproducibility of the	Neither response	Histopathological	Confirmed that the	Histopathologic groups were
correlated with the class	classification was	to therapy nor	classification	histopathological	not associated with eGFR
initial SCr and seen	seen only in patients	outcome was	predicted response to	classification has	at 3 years.
proteinuria levels. with	with sclerotic patterns	influenced by	therapy and 2-year	prognostic value and	More patients in the crescentic
The probability of of gl	of glomerular injury.	ANCA specificity	eGFR, with poorer	is a useful tool for renal	group than in the mixed
worsening renal Inter	Interstitial injury,	or by the	remission rate for	survival. Suggests a	and focal groups developed
outcome and mortality scler	sclerotic pattern and	histopathological	sclerosing group and	subdivision of	ESRD (33%, 13% and 5%
increased with decr	decreased kidney	class.	those with <25%	crescentic category	respectively).
sequence of focal, func	function predicted		normal glomeruli,	$(< \text{and} \ge 75\% \text{ of})$	Age and baseline eGFR
crescentic, mixed and poor	poor outcomes.		but did not predict	crescents) based on the	predicted renal function at
sclerotic groups.			renal nor patient survival.	different survival rates.	3 years.

^b Mean (SD or range)

^a Median (IQR)

disease

influence the distribution of the renal histopathological classes among populations.

Single-center and multicentric studies worldwide have validated the renal histopathologic classification proposed by Berden et al. in different ethnic groups. The distribution of the four renal histological categories is similar in Europe, Canada, India, and China, with crescentic class being the dominant, whereas in Japan, the focal class predominates, and in USA and in UK, the mixed class is more prevalent [26, 28–45]. Of special interest are geographical regions such as Australia, where equal distribution of the focal, crescentic, and mixed histological classes is seen, and Mexico, where mixed and sclerotic classes are the more prevalent [46, 47].

The histological classification has also been validated in 40 pediatric patients with ANCA-associated glomerulonephritis from a single-center in Canada, demonstrating that the most frequent histological class in this group was crescentic (50%), and supporting the clinical utility of the classification and its ability to discriminate renal outcomes in children with AAV [48].

Tables 1, 2, 3 summarize the main studies that have validated the histological classification.

Perspectives

The renal histological classification of ANCA-associated glomerulonephritis has raised the conduction not only of validation studies, but also of other studies focused on specific clinical correlations. An example of this is a study from the EUVAS group that found that ear, nose, and throat involvement in AAV patients was associated with favorable renal biopsy findings (less interstitial fibrosis and tubular atrophy and a more favorable histological class), as well as better renal function [50].

The studies that have validated the histological classification have provided information regarding its predictive value with respect to renal survival, but only few studies have addressed the interobserver variation. Another question that remains unanswered is whether the classification identifies specific lesions most likely to respond to one or more specific immunosuppressive agents [32]. In this regard, it should be considered that classifications are likely of greater value for evaluating the appropriateness and equivalency of patient cohorts for clinical studies rather than for use in routine clinical practice.

It also remains to be determined the impact of the lack of inclusion of the tubulointerstitial parameters in the classification, since these factors have shown to be of predictive value in the long-term renal outcome [49]. In this regard, the recently published Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of glomerulonephritis [51] suggest reporting additional features besides the prognostic class, such as clinicopathological features (e.g., GPA), percentages of focal glomerulosclerosis, tubular atrophy and interstitial fibrosis, as well as the gravity (mild, moderate or severe) of vascular changes (arteriosclerosis and arteriolosclerosis).

Despite these unsolved issues, the classification has achieved the goals of any classification system: it enhances the communication between experts in the field; provides a logical structure for the categorization of groups of patients for epidemiological, prognostic, or interventional studies; it assists in the clinical management of individual patients and includes categories that are mutually exclusive and predictive of the disease prognosis [52].

Conclusions

The renal histopathologic classification for ANCA-associated glomerulonephritis provides a logical structure for the categorization of patients into four classes defined according to glomerular lesions. The validation studies have demonstrated its reproducibility, its utility as a clinical tool, and the predictive value with respect to renal outcome.

Compliance with ethical standards

Conflicts of interest The authors declare no conflicts of interest. The manuscript does not contain clinical studies or patient data.

References

- Ereshefsky M (2001) Philosophy of biological classification. Encyclopedia of life sciences. John Wiley & Sons, New York
- Bajema IM (2011) Pathological classification of anti-neutrophil cytoplasmic antibody (ANCA) associated glomerulonephritis. Clin Exp Immunol 164(Suppl.1):14–16
- Holle JU, Laudien M, Gross WL (2010) Clinical manifestations and treatment of Wegener's Granulomatosis. Rheum Dis Clin N Am 36: 507–526
- Chung SA, Seo P (2010) Microscopic polyangiitis. Rheum Dis Clin N Am 36:545–558
- Sinico RA, Di Toma L, Radice A (2013) Renal involvement in antineutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev 12:477–482
- Chen M, Kallenberg CG, Zhao MH (2009) ANCA-negative pauciimmune crescentic glomerulonephritis. Nat Rev Nephrol 5:313– 318
- Eisenberger U, Fakhouri F, Vanhille P et al (2005) ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 20:1392–1399
- Hauer HA, Bajema IM, van Houwelingen HC et al (2002) Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 61:80–89
- Shah S, Havill J, Rahman MH et al (2016) A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonepritis. Clin Rheumatol 35:953–960

- Bajema IM, Hagen EC, Hansen BE et al (1996) The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. Nephrol Dial Transplant 11: 1989–1995
- Joh K, Muso E, Shigematsu H et al (2008) Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan. Clin Exp Nephrol 12:277–291
- Rutgers A, Sanders JS, Stegeman CA, Kallenberg CG (2010) Pauci-immune necrotizing glomerulonephritis. Rheum Dis Clin N Am 36:559–572
- Rhee RL, Hogan SL, Poulton CJ et al (2016) Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis Rheum 68:1711–1720
- Kaplan-Pavlovcic S, Cerk K, Kveder R, Lindic J, Vizjak A (2003) Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant 18(Suppl 5):v5–v7
- Hauer HA, Bajema IM, Van Houwelingen HC et al (2002) Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis in 96 patients. Kidney Int 62:1732–1742
- de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R et al (2006) Clinical and histologic determinants of renal outcome in ANCAassociated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 17:2264–2274
- de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R et al (2007) Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol 18:2189–2197
- Neumann I, Kain R, Regele H, Soleiman A, Kandutsch S, Meisl FT (2005) Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant 20:96–104
- Bajema IM, Hagen EC, Hermans J et al (1999) Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 56:1751–1758
- Hauer HA, Bajema IM, Hagen EC et al (2002) Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. Nephrol Dial Transplant 17:587–596
- 21. Shigematsu H, Yamaguchi N, Koyama A (1998) Glomerulointerstitial events in rapidly progressive nephritic syndrome, with special reference to histologic grade and stage on the renal lesions. Clin Exp Nephrol 2:330–338
- Vergunst CE, van Gurp E, Hagen EC et al (2003) EC/BCR project for ANCA-assay standardization. An index for renal outcome in ANCA-associated glomerulonephritis. Am J Kidney Dis 41:532– 538
- 23. Allison SJ (2010) ANCA-associated glomerulonephritis: a new histopathological classification. Nat Rev Nephrol 6:689
- 24. Jayne D, Rasmussen N, Andrassy K et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44
- 25. Jayne DRW, Gaskin G, Rasmussen N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjuntive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180–2188
- Berden AE, Ferrario F, Hagen EC et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21:1628–1636
- Kobayashi S, Fujimoto S (2013) Epidemiology of vasculitides: differences between Japan, Europe and North America. Clin Exp Nephrol 17:611–614
- Geetha D, Poulton CJ, Hu Y et al (2014) Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. Semin Arthritis Rheum 43:778–783

- Chang DY, Wu LH, Liu G, Chen M, Kallenberg CG, Zhao MH (2012) Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant 27:2343–2349
- Ellis CL, Manno RL, Havill JP, Racusen LC, Geetha D (2013) Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome. BMC Nephrol 14:210
- Iwakiri T, Fujimoto S, Kitagawa K et al (2013) Validation of a newly porposed histopahological classification in Japanese patients with antineutrophil cytoplasmic antibody-assocaited glomerulonephritis. BMC Nephrol 14:125
- Haas M, Rastaldi MP, Fervenza FC (2014) Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. Kidney Int 85:779–793
- Nohr E, Girard L, James M, Benediktsson H (2014) Validation of a histopathologic classification scheme for antineutrophil cytoplasmic antibody-associated glomerulonephritis. Hum Pathol 45: 1423–1429
- Andreiana I, Stancu S, Avram A, Taran L, Mircescu G (2015) ANCA positive crescentic glomerulonephritis outcome in a central east European cohort: a retrospective study. BMC Nephrol 16:90
- 35. Li ZY, Gou SJ, Chen M, Zhao MH (2013) Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: a study of 89 cases in a single Chinese center. Semin Arthritis Rheum 42:515–521
- Togashi M, Komatsuda A, Nara M et al (2014) Validation of the 2010 histopathological classification of ANCA-associated glomerulonephritis in a Japanese single-center cohort. Mod Rheumatol 24: 300–303
- Unlu M, Kiremitci S, Ensari A et al (2013) Pauci-immune necrotizing crescentic glomerulonephritis with crescentic and full moon extracapillary proliferation: clínico-pathologic correlation and follow-up study. Pathol Res Pract 209:75–82
- Hilhorst M, Wilde B, van Breda VP, van Paassen P, Cohen Tervaert JW, Limburg Renal Registry (2013) Estimating renal survival using the ANCA-associated GN classification. J Am Soc Nephrol 24: 1371–1375
- 39. Muso E, Endo T, Itabashi M et al (2013) Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibodyassociated glomerulonephritis in comparison with other Asian and European cohorts. Clin Exp Nephrol 17:659–662
- Hilhorst M, Wilde B, van Paassen P et al (2013) Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 28:373–379
- 41. Tanna A, Guarino L, Tam FW et al (2015) Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant 30:1185–1192
- 42. Quintana LF, Peréz NS, De Sousa E et al (2014) ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 29:1764–1769
- 43. Naidu GS, Sharma A, Nada R et al (2014) Histopathological classification of pauci-immune glomerulonephritis and its impact on outcome. Rheumatol Int 34:1721–1727
- Diaz-Crespo F, Villacorta J, Acevedo M et al (2016) The predictive value of kidney biopsy in renal vasculitis: a multicentre cohort study. Hum Pathol S0046-8177(16):00048–00044. doi:10.1016/j. humpath.2016.01.015
- 45. Kristensen T, Gregersen JW, Krag SR et al (2016) The relation between histopathological classification and renal outcome,

ANCA subtype and treatment regimens in ANCA-associated vasculitis. Clin Exp Rheumatol 34(Suppl 97):S105–S110

- 46. Ford SL, Polkinghorne KR, Longano A et al (2014) Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. Am J Kidney Dis 63:227–235
- Córdova-Sánchez BM, Mejía-Vilet JM, Morales-Buenrostro LE, Loyola-Rodríguez G, Uribe-Uribe NO, Correa-Rotter R (2016) Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCAassociated vasculitis with renal involvment. Clin Rheumatol. doi: 10.1007/s10067-016-3195-z
- Noone DG, Twilt M, Hayes WN et al (2014) The new histopathologic classification of ANCA-associated GN and its association with renal outcomes in childhood. Clin J Am Soc Nephrol 9: 1684–1691
- Berden AE, Jones RB, Erasmus DD et al (2012) Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibodyassociated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 23:313–321
- 50. Rahmattulla C, de Lind van Wijngaarden RA, Berden AE et al (2015) Renal function and ear, throat involvement in antineutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. Rheumatology (Oxford) 54:899–907
- Sethi S, Haas M, Markowitz GS et al (2016) Mayo Clinic/Renal Pathology Society consensus report on pathologic classification, diagnosis, and reporting on GN. J Am Soc Nephrol 27:1278–1287
- Glassock RJ (2004) Reclassification of lupus glomerulonephritis: back to the future. J Am Soc Nephrol 15:501–503